Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0178874 (tumor progression)
 40,807 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An experimental system was developed that permitted nonrandom chromosome changes that occur in radiation leukemia virus (RadLV)-induced lymphomas to be followed during tumor progression. RadLV variant-induced preleukemia and leukemia cells originating from female inbred C57BL/6 mice were injected into male animals of the same strain. Since all donors were females and all recipients were males, the sex chromosome complements (XX and XY) were used to distinguish the preleukemia and leukemia cells from those of host origin. The G-banding analysis revealed that more than 50% of animals that were inoculated with preleukemia cells and that developed leukemia possessed tumor stem-lines of 41 chromosomes with a tristomy of chromosome #15. In animals inoculated with overt leukemia cells and in which tumor progression occurred, the G-banding an additional trisomy of chromosome #17. The cytogenic data strongly suggested that the trisomy of chromosome #15 was the first specific tumor-associated chromosome change that occurred in the process of conversion of RadLV-induced preleukemia cells to fully autonomous tumor cells.
J Natl Cancer Inst 1978 Jul
PMID:Chromosome changes (trisomies #15 and 17) associated with tumor progression in leukemias induced by radiation leukemia virus. 20 3

Twenty-nine patients with recurrent malignant brain tumors were evaluated. BCNU (180 mg/m2) was administered iv on Day 1 and 5-fluorouracil (1 g/m2/day) was given by continuous infusion on Days 15--17. Courses were repeated every 6 weeks until tumor progression occurred. Before each course, a neurologic examination and radionuclide and computerized tomographic scans were performed. Response and progression were defined as improvement or deterioration, respectively, in at least two of the three tests. Nine of 29 patients (31%) responded to therapy, five of 29 (17%) showed progression, and 15 of 29 (52%) had disease stability. The estimated median time to progression was 27 weeks for all patients, 34 weeks for the response group, and 25 weeks for the stable group. Of all 29 patients, 24 (83%) had tumor progression arrested; 40% with response and 6% with stable disease were continuing therapy after 1 year. The stable disease group was larger and the duration of stability was longer than that seen in previous studies. Evaluated by time to progression, a BCNU-5-fluorouracil combination is superior to either BCNU alone or a BCNU-procarbazine combination.
Cancer Treat Rep 1978 Dec
PMID:BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors. 22 Nov 13

Twenty-one patients with grade III or IV astrocytomas were assigned randomly to receive either BCNU alone or BCNU and VM-26 after surgery and radiation therapy. Patients surviving radiation therapy and receiving single-agent chemotherapy had a median survival of 14 months while those receiving combination chemotherapy had a median survival of 22 months (P greater than 0.05). None of the patients who failed BCNU-only therapy responded to VM-26. Performance status was not affected by either regimen. Computerized tomographic scanning of the brain was useful only in confirming tumor progression. Two patients died from BCNU-related interstitial pulmonary fibrosis.
Cancer Treat Rep
PMID:Treatment of grade III and IV astrocytomas with BCNU alone and in combination with VM-26 following surgery and radiation therapy. 23 Aug 93

Cis-Dichlorodiammineplatinum (II) was administered in 23 patients with far advanced solid malignancies using a dose schedule of 50 mg/m2 every 3 weeks. All patients had previously progressive disease using conventional cytotoxic therapies. More than 50% of the patients had been pretreated with at least 4 different drugs. 9 patients, additionally, had been irradiated. In 4 instances there was objective tumor regression (duration: 1 to 4 months), in 7 patients tumor progression could be stopped for at least one month, 12 patients did not respond. By sufficient fluid administration combined with electrolyte substitution, furosemide and mannitol, no severe toxic side effects could be observed.
 ...
PMID:[Experiences with cis-dichlorodiaminoplatinum (II) in the treatment of advanced solid tumors]. 29 24

The author reports the results of studying 311 reactions of lymphocyte blasttransformation, 74 reactions of spontaneous rosette-formation and 186 reactions of plaque-formation in 184 patients with different stages of cervical cancer. It was found that in the tumor progression cell immunity indices are lowered and the degree of the lowering is dependent on the form of tumor growth. Radiotherapy results in the enhancement of autoantibody-formation processes and suppresses the response of lymphocytes to PHA found to be mostly pronounced in patients with advanced cancer. The blasttransformation reaction correlates well with the number of peripheral blood lymphocytes, and during radiotherapy the former slows down before the routinely revealed lymphopenia, that allows using this reaction to prognosticate lymphopenia. The most large amounts of plaque-forming blood cells were detected in patients with radiation injuries of the adjacent to the uterus organs of the small pelvis. Use of lymphocyte blasttrasformation reaction and quantitation of plaque-forming blood cells may provide the grounds for the individual application of radiotherapy for cervical cancer to increase its effectiveness.
 ...
PMID:[Control of the immunological reactivity in cervical cancer in the process of radiation therapy]. 31 45

Antiestrogen compounds are relatively new in the treatment of breast cancer. A clinical trial of Nafoxidine therapy is being pursued in our institution. In a selected group of patients with metastatic breast cancer who had, in the past, undergone adrenalectomy, Nafoxidine therapy produced objective tumor regression in six out of ten patients. Of the six patients whose tumors contained demonstrable estrogen receptors, four showed regression (67%), one patient had stable disease, and one showed tumor progression. Of the four patients in whom estrogen receptor estimation was not done, two had, in the past, shown regression after endocrine therapy and they also showed regression of tumor with Nafoxidine therapy. In patients with metastatic breast carcinoma, who have undergone adrenalectomy in the past, a therapeutic trial with Nafoxidine may be worthwhile particularly in patients who have demonstrable estrogen receptor in the tumor of those who have in the past shown regression of tumor after endocrine therapy.
Cancer 1977 Nov
PMID:Clinical trial of nafoxidine in adrenalectomized patients with advanced breast cancer. 33 79

Eighteen patients with advanced metastatic malignancy who had 21 pleural effusions requiring sclerosis for control were randomly allocated to intrapleural therapy with tetracycline or quinacrine. Tetracycline produced partial or complete control of the effusion in ten of 12 trials for a median duration of 6 months (range 1.5 to 22 months). Partial or complete control was obtained in nine of ten trials with quinacrine, for a median duration of 3 months (range 1 to 13 months). All complete responders who died achieved control of their effusions until their terminal admissions despite clinical evidence of overt systemic tumor progression in the intervening period. Single-dose tetracycline therapy was accompanied by less fever (p less than 0.04) and less pleuritic pain (p = 0.09) than quinacrine. Tetracycline is effective, well tolerated, easily administered, and should be considered as the initial therapy for malignant pleural effusions requiring pleural sclerosis.
Cancer 1978 Mar
PMID:Tetracycline and quinacrine in the control of malignant pleural effusions. A randomized trial. 34 89

Hormonal responsiveness should be considered in terms of at least three homeostatic constraint mechanisms. Observations on the induction of specific responses in rat prostate reveal that certain of these are controlled differentially, and also that immature cells can be modified by low levels of androgen. The conditioning effect of low levels of steroid is further demonstrated by the benefits of fractional hormone-replacement therapy in controlling and delaying tumor progression. A revised approach to endocrine therapy of cancer should be seriously considered. This would entail the fractional replacement of hormone after ablative surgery.
 ...
PMID:Pathological growth of androgensensitive tissues resulting from latent actions of steroid hormones. 35 Dec 3

To determine the efficacy and toxicity of cis-dichlorodiammineplatinum(II) (DDP) by a continuous iv infusion (CIVI) schedule, 34 patients with a variety of solid tumors were studied. All patients were refractory to prior chemotherapy and received a loading dose of 5 mg/m2 of DDP iv followed by 20 mg/m2 by CIVI daily for 5 days. In 25 evaluable patients, there were four (16%) complete or partial responders, nine (25%) with stable disease, and 12 (48%) with tumor progression. One complete and one partial remission were seen in two patients with disseminated basal cell carcinoma, with partial responses also seen in cervical and head and neck squamous cancer. Patients experienced renal damage (21%) and audiotoxicity (10%). Nausea and vomiting was severe in only 6%. DDP by CIVI appears to have comparable toxicity to DDP administered by other schedules; however, the diminished gastrointestinal toxicity makes the drug better tolerated by patients for whom the inconvenience of a 5-day hospitalization is less than that caused by the nausea and vomiting of rapid infusion programs.
Cancer Treat Rep 1978 Oct
PMID:Clinical phase I-II study of cis-dichloro-diammineplatinum(II) given by continuous lv infusion. 36 Dec 27

A rat liver cell line, Lew A1, was isolated from W/LEW rats. It had the normal female karyotype in the lower passage numbers, but in the higher passages it was aneuploid. This line was passaged 65 times, produced rat serum albumin, and consisted of an apparently homogeneous population of typical epithelial cells. The cells also had high levels of the inducible aryl hydrocarbon hydroxylase enzyme complex. A series of experiments described here defined the normal clonal behavior of this line and its modification by repeated treatments with a carcinogenic polycyclic hydrocarbon, 7,12-dimethylbenz[a]anthracene. The results were discussed with particular reference to metastasis, preneoplastic changes, and neoplastic progression.
J Natl Cancer Inst 1977 Sep
PMID:Clonal behavior of a rat liver cell line and its modification by repeated treatments with a carcinogenic polycyclic hydrocarbon. 40 4


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>